Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 05, 2024

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
J. Clin. Oncol 2024 Jan 08;[EPub Ahead of Print], L Moreno, R Weston, C Owens, D Valteau-Couanet, M Gambart, V Castel, CM Zwaan, K Nysom, N Gerber, A Castellano, G Laureys, R Ladenstein, J Rössler, G Makin, D Murphy, B Morland, S Vaidya, E Thebaud, N van Eijkelenburg, DA Tweddle, G Barone, J Tandonnet, N Corradini, P Chastagner, C Paillard, FJ Bautista, S Gallego Melcon, B De Wilde, L Marshall, J Gray, SA Burchill, G Schleiermacher, L Chesler, A Peet, MO Leach, K McHugh, R Hayes, N Jerome, H Caron, J Laidler, N Fenwick, G Holt, V Moroz, P Kearns, S Gates, ADJ Pearson, K Wheatley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading